Invest and Make a Difference
With LTX, investors get an opportunity to invest in a breakthrough product and a company that makes a real difference in the lives of critically ill patients in the ICU.
As a company, the probability of success for LTX is very high. The phase 3 primary endpoint for Niyad will be met by proving it anti-coagulates blood – and it always will. So LTX is a private biotech with a high probability of return on investment.